Everolimus was the first mTOR inhibitor to be approved by the FDA in combination with steroidal AI for the treatment of ER+/HER2− ABC patients who progressed after exposure to non-steroidal AI as first-line therapy [71]. This evidence concerns the gene ESR1 and aneurysmal bone cyst.